Lupus Nephritis Biomarkers: A Critical Review
暂无分享,去创建一个
[1] Guangchang Pei,et al. Identification of driver genes in lupus nephritis based on comprehensive bioinformatics and machine learning , 2023, Frontiers in immunology.
[2] G. Tsokos,et al. The immunoregulatory roles of non-haematopoietic cells in the kidney. , 2023, Nature reviews. Nephrology.
[3] M. Gatto,et al. Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis , 2023, International journal of molecular sciences.
[4] H. Ding,et al. Biomarkers for systemic lupus erythematosus – a focus on organ damage , 2023, Expert review of clinical immunology.
[5] C. Vinuesa,et al. Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants , 2023, Nature Reviews Nephrology.
[6] C. Putterman,et al. Pathogenic cellular and molecular mediators in lupus nephritis , 2023, Nature Reviews Nephrology.
[7] S. Bang,et al. Higher Genetic Risk Loads Confer More Diverse Manifestations and Higher Risk of Lupus Nephritis in Systemic Lupus Erythematosus , 2023, Arthritis & rheumatology.
[8] H. Hsu,et al. Interrelation of T cell cytokines and autoantibodies in systemic lupus erythematosus: A cross-sectional study. , 2023, Clinical immunology.
[9] Binh V Vu,et al. A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM , 2022, Frontiers in Immunology.
[10] K. Lindblad-Toh,et al. Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease , 2022, Lupus Science & Medicine.
[11] Q. Lu,et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study , 2022, Annals of the Rheumatic Diseases.
[12] B. Mori,et al. Diagnostic test accuracy of novel biomarkers for lupus nephritis—An overview of systematic reviews , 2022, PloS one.
[13] C. Mohan,et al. Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis. , 2022, Rheumatology.
[14] John G Kenny,et al. Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE , 2022, Rheumatology.
[15] T. Andrews,et al. TLR7 gain-of-function genetic variation causes human lupus , 2022, Nature.
[16] Tianfu Wu,et al. Discovery of Novel Circulating Immune Complexes in Lupus Nephritis Using Immunoproteomics , 2022, Frontiers in Immunology.
[17] A. Roointan,et al. Candidate MicroRNA Biomarkers in Lupus Nephritis: A Meta-analysis of Profiling Studies in Kidney, Blood and Urine Samples , 2022, Molecular Diagnosis & Therapy.
[18] M. Petri,et al. The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses , 2022, The Journal of clinical investigation.
[19] H. Hsu,et al. Lupus nephritis correlates with B cell interferon-β, anti-Smith, and anti-DNA: a retrospective study , 2021, Arthritis Research & Therapy.
[20] N. Hacohen,et al. Urine Proteomics and Renal Single‐Cell Transcriptomics Implicate Interleukin‐16 in Lupus Nephritis , 2021, Arthritis & rheumatology.
[21] M. Khamashta,et al. 10 Years of belimumab experience: What have we learnt? , 2021, Lupus.
[22] A. Syvänen,et al. Variants in BANK1 are associated with lupus nephritis of European ancestry , 2021, Genes & Immunity.
[23] B. Heijs,et al. Protein Mannosylation as a Diagnostic and Prognostic Biomarker of Lupus Nephritis: An Unusual Glycan Neoepitope in Systemic Lupus Erythematosus , 2021, Arthritis & rheumatology.
[24] R. Cummings,et al. Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis , 2021, JCI insight.
[25] D. Yap,et al. Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis , 2021, Lupus.
[26] D. Zack,et al. A Review of Complement Activation in SLE , 2021, Current Rheumatology Reports.
[27] Y. Qi,et al. Albumin-to-globulin ratio (AGR) as a potential marker of predicting lupus nephritis in Chinese patients with systemic lupus erythematosus , 2021, Lupus.
[28] K. Shalaby,et al. Urinary Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (uTWEAK) and Urinary Monocyte Chemo-attractant Protein-1 (uMCP-1): Promising Biomarkers of Lupus Nephritis Activity? , 2021, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
[29] M. Prunotto,et al. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. , 2020, Rheumatology.
[30] F. Yu,et al. The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients , 2020, Frontiers in Immunology.
[31] S. Hassan,et al. Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus , 2020, Lupus.
[32] I. Bruce,et al. A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. , 2020, Rheumatology.
[33] C. Bao,et al. The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients , 2020, PloS one.
[34] L. Quintana,et al. Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis , 2020, Clinical Rheumatology.
[35] C. Mohan,et al. Targeted urine proteomics in lupus nephritis – a meta-analysis , 2020, Expert review of proteomics.
[36] A. Blom,et al. Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients , 2020, Frontiers in Immunology.
[37] H. Nagaraja,et al. Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis , 2020, Arthritis & rheumatology.
[38] Ranjan Gupta,et al. Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis , 2020, Clinical Rheumatology.
[39] J. Redón,et al. Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis , 2020, Journal of Nephrology.
[40] M. Petri,et al. Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis , 2020, Annals of the Rheumatic Diseases.
[41] I. Bruce,et al. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment , 2020, RMD Open.
[42] Bin Wang,et al. Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis , 2020, BioMed research international.
[43] P. Schaefer,et al. Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis , 2020, BMC Rheumatology.
[44] C. Mohan,et al. Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology , 2020, Arthritis Research & Therapy.
[45] H. Lee,et al. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis , 2020, Lupus.
[46] T. Tuschl,et al. Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities , 2020, Nature Communications.
[47] T. Kishimoto,et al. Translating IL-6 biology into effective treatments , 2020, Nature Reviews Rheumatology.
[48] H. Nagaraja,et al. Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis. , 2020, Journal of the American Society of Nephrology : JASN.
[49] L. Magder,et al. Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis , 2020, The Journal of Rheumatology.
[50] M. Petri,et al. Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages , 2020, Frontiers in Immunology.
[51] D. Ye,et al. Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis , 2020, Lupus.
[52] D. Häussinger,et al. Dead Cells Induce Innate Anergy via Mertk after Acute Viral Infection. , 2020, Cell reports.
[53] E. Frangou,et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.
[54] E. Ballestar,et al. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases , 2020, Arthritis & rheumatology.
[55] Xuejun Zhang,et al. Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity , 2020, Human molecular genetics.
[56] M. Inanç,et al. Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus , 2020, Lupus.
[57] D. Ye,et al. Urinary Tumor Necrosis Factor–Like Weak Inducer of Apoptosis as a Biomarker for Diagnosis and Evaluating Activity in Lupus Nephritis , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[58] T. Moliné,et al. The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis , 2020, International journal of molecular sciences.
[59] J. Shang,et al. Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody , 2020, Renal failure.
[60] H. Anders,et al. Lupus nephritis , 2020, Nature Reviews Disease Primers.
[61] J. A. Gómez-Puerta,et al. Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis. , 2020, Reumatologia clinica.
[62] Paul J. Hoover,et al. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. , 2019, Seminars in arthritis and rheumatism.
[63] A. Larsson,et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus , 2019, Rheumatology.
[64] M. Selvaraja,et al. Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis , 2019, PloS one.
[65] Michael A. Smith,et al. SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus , 2019, Scientific Reports.
[66] J. Pfeilschifter,et al. Blood ceramides as novel markers for renal impairment in systemic lupus erythematosus. , 2019, Prostaglandins & other lipid mediators.
[67] S. Eiam‐Ong,et al. Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis , 2019, International journal of molecular sciences.
[68] Elizabeth S Kotzen,et al. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. , 2019, Advances in chronic kidney disease.
[69] T. Moliné,et al. Urinary Neuropilin-1: A Predictive Biomarker for Renal Outcome in Lupus Nephritis , 2019, International journal of molecular sciences.
[70] M. Petri,et al. Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis , 2019, Arthritis Research & Therapy.
[71] Guo-min Li,et al. Expanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report , 2019, BMC Medical Genetics.
[72] A. Paterson,et al. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. , 2019, Rheumatology.
[73] H. Anders. Nephropathic autoantigens in the spectrum of lupus nephritis , 2019, Nature Reviews Nephrology.
[74] Nir Hacohen,et al. The immune cell landscape in kidneys of patients with lupus nephritis , 2019, Nature Immunology.
[75] S. Rajalingham,et al. Serum and urine interleukin‐17A levels as biomarkers of disease activity in systemic lupus erythematosus , 2019, International journal of rheumatic diseases.
[76] Hu Dedong,et al. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients. , 2019, Immunology letters.
[77] C. Mohan,et al. Identification of Low‐Abundance Urinary Biomarkers in Lupus Nephritis Using Electrochemiluminescence Immunoassays , 2019, Arthritis & rheumatology.
[78] Jie Du,et al. The clinical significance of plasma CFHR 1-5 in lupus nephropathy. , 2019, Immunobiology.
[79] S. Zununi Vahed,et al. Plasma levels of miR-21, miR-150, miR-423 in patients with lupus nephritis. , 2019, Iranian journal of kidney diseases.
[80] C. Zeng,et al. Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[81] T. Hsieh,et al. Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study , 2019, Lupus.
[82] Kamil Slowikowski,et al. Tubular Cell and Keratinocyte Single-cell Transcriptomics Applied to Lupus Nephritis Reveal Type I IFN and Fibrosis Relevant Pathways , 2019, Nature Immunology.
[83] W. Wang,et al. Anti–α-enolase antibody combined with β2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients , 2019, Lupus.
[84] C. Mohan,et al. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis , 2019, PloS one.
[85] Ming-Yang Chang,et al. Polyomavirus BK, BKV microRNA, and urinary neutrophil gelatinase-associated lipocalin can be used as potential biomarkers of lupus nephritis , 2019, PloS one.
[86] T. Nishino,et al. Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. , 2018, Clinical immunology.
[87] S. Mowla,et al. Elevated expression of miR‐21 and miR‐155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis , 2018, International journal of rheumatic diseases.
[88] P. Kerr,et al. Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus , 2018, Lupus.
[89] L. Chiriboga,et al. Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. , 2018, Seminars in arthritis and rheumatism.
[90] J. Xie,et al. Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study , 2018, International immunopharmacology.
[91] E. Yi,et al. Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare , 2018, Lupus.
[92] L. Criswell,et al. Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients , 2018, PloS one.
[93] Bin Zhou,et al. Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity , 2018, Medicine.
[94] H. Sibaii,et al. Increased level of B cell differentiation factor in systemic lupus erythematosus patients , 2018, Journal, genetic engineering & biotechnology.
[95] S. Zununi Vahed,et al. Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis , 2018, BioImpacts : BI.
[96] M. Sanak,et al. Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis , 2018, Lupus.
[97] Agnes B. Fogo,et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. , 2018, Kidney international.
[98] R. Cervera,et al. Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients , 2018, Lupus.
[99] S. Thiel,et al. The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus , 2018, Front. Immunol..
[100] M. Hemida,et al. Urinary neutrophil gelatinase-associated lipocalin as a marker for disease activity in lupus nephritis , 2018, Scandinavian journal of clinical and laboratory investigation.
[101] Jing-Long Huang,et al. Urinary clusterin—a novel urinary biomarker associated with pediatric lupus renal histopathologic features and renal survival , 2018, Pediatric Nephrology.
[102] M. Salem,et al. Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis , 2018, Zeitschrift für Rheumatologie.
[103] E. Bonfá,et al. Serum uric acid levels are associated with lupus nephritis in patients with normal renal function , 2018, Clinical Rheumatology.
[104] C. Mohan,et al. Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis , 2018, Arthritis Research & Therapy.
[105] D. Kastner,et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease , 2018, Annals of the rheumatic diseases.
[106] A. Blom,et al. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus , 2017, Arthritis Research & Therapy.
[107] M. Petri,et al. Epidemiology of systemic lupus erythematosus: an update , 2017, Current opinion in rheumatology.
[108] H. Anders,et al. Toll-like receptor activation in the pathogenesis of lupus nephritis. , 2017, Clinical immunology.
[109] C. Pusey,et al. Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy , 2017, Kidney international.
[110] C. Mohan,et al. Urine angiostatin and VCAM‐1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis , 2017, International journal of rheumatic diseases.
[111] B. Satirapoj,et al. Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis , 2017, BMC Nephrology.
[112] R. Valdez-Ortiz,et al. Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: An exploratory study. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
[113] A. Larsson,et al. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis , 2017, Scandinavian journal of rheumatology.
[114] Yunfeng Zhu,et al. Regulation of MiR-146a and TRAF6 in the Diagnose of Lupus Nephritis , 2017, Medical science monitor : international medical journal of experimental and clinical research.
[115] Q. Lu,et al. Organ-specific biomarkers in lupus. , 2017, Autoimmunity reviews.
[116] S. Chaurasia,et al. Urinary B cell activating factor (BAFF) and a proliferation‐inducing ligand (APRIL): potential biomarkers of active lupus nephritis , 2017, Clinical and experimental immunology.
[117] D. Ye,et al. Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus , 2017, Oncotarget.
[118] P. Nilsson,et al. Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study , 2017, Lupus.
[119] S. Maruyama,et al. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[120] Ming-hui Zhao,et al. Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. , 2016, Kidney international.
[121] Mansour Babaei,et al. Serum alpha–actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis , 2016, Caspian journal of internal medicine.
[122] M. Kharboutli,et al. Axl, Ferritin, Insulin‐Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus , 2016, Arthritis care & research.
[123] M. Petri,et al. Development of Biomarker Models to Predict Outcomes in Lupus Nephritis , 2016, Arthritis & rheumatology.
[124] M. Petri,et al. Anti-C1q in systemic lupus erythematosus , 2016, Lupus.
[125] M. Petri,et al. Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. , 2016, Journal of proteome research.
[126] R. Zhong,et al. Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus , 2016, Journal of clinical laboratory analysis.
[127] Andreas Radbruch,et al. Plasma cells as an innovative target in autoimmune disease with renal manifestations , 2016, Nature Reviews Nephrology.
[128] C. Putterman,et al. Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis , 2016, PloS one.
[129] A. Fatemi,et al. Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study , 2016, Modern rheumatology.
[130] V. Negi,et al. Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity , 2016, Lupus.
[131] J. Choe,et al. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus , 2016, Inflammation Research.
[132] J. Harley,et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification , 2016, Annals of the rheumatic diseases.
[133] H. Nagaraja,et al. Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[134] Y. Wang,et al. Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody , 2016, Medicine.
[135] S. Yung,et al. Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis , 2016, Lupus.
[136] V. Tesar,et al. Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up , 2015, Arthritis Research & Therapy.
[137] S. Sun,et al. Urinary neutrophil gelatinase-associated lipocalin for diagnosis and estimating activity in lupus nephritis: a meta-analysis , 2015, Lupus.
[138] S. Möller,et al. Secondary necrotic neutrophils release interleukin-16C and macrophage migration inhibitory factor from stores in the cytosol , 2015, Cell Death Discovery.
[139] R. Saxena,et al. Insulin‐like growth factor binding protein‐2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis , 2015, Clinical and experimental immunology.
[140] J. Ordi‐Ros,et al. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[141] G. Ghiggeri,et al. Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. , 2015, Autoimmunity reviews.
[142] C. Putterman,et al. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis , 2015, Nature Reviews Nephrology.
[143] Hong Zhang,et al. Human neutrophil peptide 1–3, a component of the neutrophil extracellular trap, as a potential biomarker of lupus nephritis , 2015, International journal of rheumatic diseases.
[144] Tianfu Wu,et al. Resistin as a potential marker of renal disease in lupus nephritis , 2015, Clinical and experimental immunology.
[145] H. Kalim,et al. Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. , 2015, Pathophysiology : the official journal of the International Society for Pathophysiology.
[146] Andreas Radbruch,et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.
[147] M. Blettner,et al. Colony-stimulating factor-1: a potential biomarker for lupus nephritis. , 2015, Journal of the American Society of Nephrology : JASN.
[148] B. Satirapoj,et al. Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients , 2015, Lupus.
[149] I. Gunnarsson,et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy , 2015, Lupus Science & Medicine.
[150] Pingan Zhang,et al. Value of HLA‐DR genotype in systemic lupus erythematosus and lupus nephritis: a meta‐analysis , 2015, International journal of rheumatic diseases.
[151] A. Scaloni,et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. , 2014, Journal of the American Society of Nephrology : JASN.
[152] J. Gran,et al. Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study , 2014, Lupus.
[153] M. Vilardell‐Tarrés,et al. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[154] J. Choe,et al. Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus , 2014, Lupus.
[155] Yuanfang Guan,et al. Identification of Stage‐Specific Genes Associated With Lupus Nephritis and Response to Remission Induction in (NZB × NZW)F1 and NZM2410 Mice , 2014, Arthritis & rheumatology.
[156] P. Gaffney,et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. , 2014, Journal of the American Society of Nephrology : JASN.
[157] A. Blom,et al. The complement system in systemic lupus erythematosus: an update , 2014, Annals of the rheumatic diseases.
[158] D. Roccatello,et al. Renal involvement in antiphospholipid syndrome , 2014, Nature Reviews Nephrology.
[159] E. Ferrannini,et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. , 2014, Autoimmunity reviews.
[160] John D Reveille,et al. End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 , 2014, Arthritis & rheumatology.
[161] A. Syvänen,et al. Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis , 2013, PloS one.
[162] P. Yip,et al. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. , 2013, Arthritis and rheumatism.
[163] G. Tsokos,et al. Gene-function studies in systemic lupus erythematosus , 2013, Nature Reviews Rheumatology.
[164] Q. Mi,et al. The regulation and function of micrornas in kidney diseases , 2013, IUBMB life.
[165] Ming-hui Zhao,et al. Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis , 2013, BMC Nephrology.
[166] Chandra Mohan,et al. Urinary Angiostatin - A Novel Putative Marker of Renal Pathology Chronicity in Lupus Nephritis* , 2013, Molecular & Cellular Proteomics.
[167] H. Anders,et al. Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non‐inflammatory glomerular injury , 2012, The Journal of pathology.
[168] Nattiya Hirankarn,et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis , 2012, Arthritis Research & Therapy.
[169] A. Doria,et al. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis , 2012, Lupus.
[170] B. Rovin,et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. , 2012, Arthritis and rheumatism.
[171] C. Putterman,et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis , 2012, Arthritis Research & Therapy.
[172] K. Matrawy,et al. Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus. , 2012, Journal of nephrology.
[173] Usha,et al. Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare , 2012, Lupus.
[174] E. Park,et al. Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1/3, and NF‐κB activation and enhances inflammatory responses in lipopolysaccharide‐induced acute lung injury , 2012, Journal of leukocyte biology.
[175] H. Anders,et al. A novel pathogenetic concept—antiviral immunity in lupus nephritis , 2012, Nature Reviews Nephrology.
[176] H. Chng,et al. Urine sVCAM‐1 and sICAM‐1 levels are elevated in lupus nephritis , 2012, International journal of rheumatic diseases.
[177] P. Gaffney,et al. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis , 2011, Genes and Immunity.
[178] G. Tsokos,et al. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. , 2011, Trends in molecular medicine.
[179] Andreas Radbruch,et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation , 2011, Nature Reviews Rheumatology.
[180] C. Winkler,et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.
[181] Igor M. Dozmorov,et al. Identification of Unique MicroRNA Signature Associated with Lupus Nephritis , 2010, PloS one.
[182] Abdul Hakkim,et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis , 2010, Proceedings of the National Academy of Sciences.
[183] M. Hegazy,et al. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. , 2010, Clinical immunology.
[184] Glinda S Cooper,et al. Understanding the epidemiology and progression of systemic lupus erythematosus. , 2010, Seminars in arthritis and rheumatism.
[185] O. Rekvig,et al. Deposition of chromatin‐IgG complexes in skin of nephritic MRL‐lpr/lpr mice is associated with increased local matrix metalloprotease activities , 2009, Experimental dermatology.
[186] Yong Dai,et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients , 2009, Rheumatology International.
[187] J. Reveille,et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. , 2008, Rheumatology.
[188] M. Petri,et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.
[189] J. Grün,et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. , 2008, Arthritis and rheumatism.
[190] G. Lemke,et al. TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.
[191] C. Suh,et al. Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus , 2007, Journal of Clinical Immunology.
[192] M. Ward,et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. , 2007, Arthritis and rheumatism.
[193] G. Lemke,et al. Macrophages and Dendritic Cells Use Different Axl/Mertk/Tyro3 Receptors in Clearance of Apoptotic Cells1 , 2007, The Journal of Immunology.
[194] G. Sturfelt,et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. , 2007, Kidney international.
[195] Fabian D. G. McGrath,et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone , 2006, Annals of the rheumatic diseases.
[196] S. Sadallah,et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[197] R. Sarisky,et al. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[198] B. Hahn,et al. Cellular and Molecular Mechanisms of Regulation of Autoantibody Production in Lupus , 2005, Annals of the New York Academy of Sciences.
[199] H. Nagaraja,et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. , 2005, Journal of the American Society of Nephrology : JASN.
[200] M. Vilardell‐Tarrés,et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. , 2004, The American journal of medicine.
[201] R Hal Scofield,et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.
[202] D. Isenberg,et al. 1 Immunopathogenesis of SLE , 1998 .
[203] D. Isenberg,et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. , 1995, Kidney international.
[204] T. Maniatis,et al. Identification and characterization of a novel repressor of beta-interferon gene expression. , 1991, Genes & development.
[205] Timothy A. Springer,et al. Adhesion receptors of the immune system , 1990, Nature.
[206] S. Pillemer,et al. Lupus nephritis: association between serology and renal biopsy measures. , 1988, The Journal of rheumatology.
[207] OUP accepted manuscript , 2022, Clinical Kidney Journal.
[208] G. Gómez,et al. Cut-off values of immunological tests to identify patients at high risk of severe lupus nephritis. , 2018, Medicina.
[209] H. Anders,et al. Cellular and Molecular Mechanisms of Autoimmunity and Lupus Nephritis. , 2017, International review of cell and molecular biology.
[210] C. Gordon,et al. Systemic lupus erythematosus , 2016, Nature Reviews Disease Primers.
[211] Zhanguo Li,et al. Anti‐histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus , 2008, Journal of clinical laboratory analysis.
[212] B. Rovin. The chemokine network in systemic lupus erythematous nephritis. , 2008, Frontiers in bioscience : a journal and virtual library.